What Now For Lonely Stada? Bain & Cinven Takeover Bid Collapses
In a surprising twist, Stada investors have not rallied behind a €5.3bn takeover bid from equity groups Bain and Cinven; analysts are baffled as to why the deal didn’t win enough support and what Stada's shareholders are hoping for now.
You may also be interested in...
Cinven and Bain seem likely to use German generics maker Stada as a nucleus around which to add smaller acquisitions, mostly in Europe, for an eventual exit by the private equity firms.
The interim management of the German generics and OTC firm Stada defends its AGM strategy as Active Ownership Capital rallies troops to fight for greater control of the supervisory board following the temporary departure of its CEO of 23 years.
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.